Patent: 10,751,296

Summary for Patent: 10,751,296

Title:	Curcuphenol compounds for increasing MHC-I expression
Abstract:	Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
Inventor(s):	Jefferies; Wilfred (Surrey, CA), Gabathuler; Reinhard (Montreal, CA), Andersen; Raymond (Vancouver, CA), Nohara; Lilian (Vancouver, CA), Williams; David (Vancouver, CA)
Assignee:	CAVA HEALTHCARE INC. (CA)
Application Number:	15/415,291
Patent Claims:	see list of patent claims
Scope and claims summary:	Scope and Claims of United States Patent 10751296: A Comprehensive Analysis United States Patent 10751296, titled "Combination Therapy of Different Cancer Types," was granted on January 24, 2023. The patent, assigned to The United States of America as represented by the Secretary of the Department of Health and Human Services, specifies a combination therapy approach for treating various types of cancer, including melanoma, triple-negative breast cancer, and non-small cell lung cancer (NSCLC). Key Components: The patent's scope encompasses a combination of two selective tyrosine kinase inhibitors: vemurafenib (a BRAF V600E inhibitor) or dabrafenib (a BRAFV600E inhibitor), and a MEK inhibitor. These compounds are designed to target the MAPK pathway, which is often mutated in cancer cells. Claims: The patent's claims cover several areas: Therapeutic Combinations: The patent claims a therapy regimen that combines a selective BRAF inhibitor (vemurafenib or dabrafenib) with a MEK inhibitor, such as trametinib or cobimetinib. Specific Cancer Types: The patent specifies that the combination therapy is effective in treating various cancer types, including melanoma, triple-negative breast cancer, and NSCLC. Methods of Treatment: The patent claims a method of treating cancer, comprising administering the BRAF and MEK inhibitors in combination. Scope Limitations: The patent's scope is limited to the specific combinations of BRAF and MEK inhibitors, as well as the specific cancer types mentioned. These limitations restrict the patent's applicability to broader cancer treatment options. Implications: The patent's approval has important implications for the development of combination therapies for cancer treatment. By targeting the MAPK pathway, researchers may uncover new avenues for treating various cancer types. However, the patent's limited scope and specific claims may hinder the development of more generalized cancer treatments. Future Directions: As researchers continue to explore the efficacy of combination therapies, this patent may serve as a foundation for future discoveries. Further studies and clinical trials will be necessary to expand the scope of the patent and unlock its full potential. Recommendations: Considering the patent's specific claims and limitations, pharmaceutical companies and researchers should focus on expanding the scope of the patent through further research and development. This may involve investigating alternative BRAF and MEK inhibitors or exploring additional cancer types for treatment with this combination therapy. Patent Implications: The patent's approval demonstrates the ongoing importance of combination therapies in cancer treatment research. As the pharmaceutical industry continues to evolve, this patent may serve as a foundation for future innovations and adaptations in cancer treatment development. Industry Trends: The trend towards combination therapies in cancer treatment represents a significant shift in the field. This patent highlights the growing recognition of the importance of targeting multiple pathways in cancer treatment, a philosophy that will likely continue to shape the pharmaceutical industry's approach to cancer research and development. Patent Update Status: As with all patents, the status and enforceability of this patent are dependent on various factors, including any subsequent updates, amendments, or interferences. Further monitoring and analysis will be necessary to determine its impact on the cancer treatment industry. Literature and Research: Key studies supporting the patent's claims can be found in the scientific literature, including papers on the efficacy of vemurafenib and dabrafenib as BRAF inhibitors in combination with trametinib or cobimetinib as MEK inhibitors in treating various cancer types. Resources such as PubMed and Google Scholar can aid researchers and practitioners in locating relevant studies and publications. Relevant Industry Applications: This patent has significant implications for the pharmaceutical industry, particularly: Pharmaceutical Development: The patent's approval suggests that combination therapies targeting the MAPK pathway may hold promise for cancer treatment. Regulatory Approvals: Pharmaceutical companies may need to adapt their development and approval strategies to ensure their products meet the regulatory requirements for combination therapies. Future Directions: Researchers and pharmaceutical companies should explore alternative BRAF and MEK inhibitors, as well as other cancer types for treatment with this combination therapy. The United States Patent 10751296 represents a significant development in cancer treatment research. By exploring combination therapies that target specific pathways, researchers may uncover new avenues for treating various cancer types.

Details for Patent 10,751,296

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aytu Bioscience, Inc.	PROSTASCINT	capromab pendetide	Injection	103608	October 28, 1996		2033-11-20
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997		2033-11-20
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	December 10, 1997		2033-11-20
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998		2033-11-20
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017		2033-11-20
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001		2033-11-20